MIMEDX to Host First Quarter 2023 Operating and Financial Results Conference Call on May 2

Rhea-AI Summary

Marietta, Ga., April 18, 2023 (GLOBE NEWSWIRE) -- MiMedx Group, a leader in placental biologics, announced it will report its first-quarter financial results for the period ending March 31, 2023, on May 2, 2023, after market close. A conference call and webcast to discuss these results will follow at 5:00 p.m. Eastern Time. Investors can access the call through U.S. and international lines provided in the announcement. A replay will be available on the company’s website for 30 days post-event. MiMedx focuses on developing placental tissue allografts and has supplied over two million products to address clinical needs in advanced wound care and surgical recovery. The company is also advancing a late-stage pipeline targeting pain reduction and improved function for knee osteoarthritis patients.

Positive

• MiMedx has supplied over two million placental allografts.
• The company is advancing a late-stage pipeline for knee osteoarthritis, aimed at decreasing pain.
• Focus on addressing unmet clinical needs in advanced wound care and surgical recovery.

Negative

• None.

MARIETTA, Ga., April 18, 2023 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), a pioneer and leader in placental biologics, today announced that it will report operating and financial results for the first quarter ended March 31, 2023 after the market close on Tuesday, May 2, 2023. The MIMEDX senior management team will host a webcast and conference call to review its results beginning at 5:00 p.m. Eastern Time on the same day.

The conference call can be accessed using the following information:

Webcast: Click here
U.S. Investors: 877-407-6184
International Investors: 201-389-0877
Conference ID: 13737183

A replay of the webcast will be available for approximately 30 days on the Company’s website at www.mimedx.com following the conclusion of the event.

About MIMEDX
MIMEDX is a pioneer and leader in placental biologics, developing and distributing placental tissue allografts to help address unmet clinical needs in multiple sectors of healthcare, including the Advanced Wound Care market as well as in surgical recovery settings. MIMEDX is also focused on advancing a promising late-stage pipeline opportunity targeted at decreasing pain and improving function for patients with knee osteoarthritis. Our products are derived from human placental tissues and processed using our proprietary methods, including the Company’s own PURION^® process. We employ Current Good Tissue Practices, Current Good Manufacturing Practices, and terminal sterilization to produce our allografts. MIMEDX has supplied over two million allografts, through both direct and consignment shipments. For additional information, please visit www.mimedx.com.

Contact:
Matt Notarianni
Investor Relations
470-304-7291
mnotarianni@mimedx.com

FAQ

When will MiMedx report its Q1 2023 results?

MiMedx will report its first-quarter financial results on May 2, 2023, after market close.

What time is MiMedx's conference call after the Q1 2023 results?

The conference call will begin at 5:00 p.m. Eastern Time on May 2, 2023.

How can I access MiMedx's Q1 2023 results conference call?

Investors can access the call through U.S. Investors: 877-407-6184 or International Investors: 201-389-0877 using the Conference ID: 13737183.

What is the focus of MiMedx's late-stage pipeline?

MiMedx's late-stage pipeline is focused on decreasing pain and improving function for patients with knee osteoarthritis.

How many allografts has MiMedx supplied?

MiMedx has supplied over two million allografts through direct and consignment shipments.